Alpha Tau Medical Ltd (DRTS)

Alpha Tau to Participate in October Investor Conferences

Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More

Alpha Tau: Approaching Massive Year-End; Pounding The Table On Potential GBM Breakthrough

Alpha Tau to Participate in September Investor Conferences

Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple Expansions

PAVmed (NASDAQ:PAVM) versus Alpha Tau Medical (NASDAQ:DRTS) Critical Contrast

Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)

Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Success

Alpha Tau Medical (NASDAQ:DRTS) Trading 7.1% Higher – Here’s Why

Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center